Snapshot from Jul 07, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Norgine

Tracked across 5 events · 32 articles · First seen Apr 07, 2026 · Last active Jun 15, 2026

Sentiment
20
Attention
4
Events
5
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 70
Business
Impact: Norgine received TGA registration for PEDMARQSI in Australia, expanding its market reach for this specialized medicine.
May 05, 2026 · 6 articles
2 0
Business
Impact: Norgine has an exclusive licensing agreement with Fennec Pharmaceuticals to commercialize PEDMARQSI in Europe, U.K., Australia, and New Zealand.
May 07, 2026 · 6 articles
4 0
Business
Impact: Norgine is the exclusive licensing partner for Fennec Pharmaceuticals' product PEDMARQSI in Europe, the UK, Australia, and New Zealand, contributing to the global commercialization of the drug.
May 14, 2026 · 6 articles
4 30
Business
Impact: Norgine has an exclusive licensing agreement with Fennec Pharmaceuticals to commercialize PEDMARQSI (PEDMARK) in Europe, U.K., Australia, and New Zealand.
Apr 07, 2026 · 7 articles
1 0
Business
Impact: Norgine is mentioned as a commercialization partner for PEDMARQSI, providing context on Fennec Pharmaceuticals' broader business activities, though not directly impacted by this specific stock option grant.
May 18, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Norgine live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.